Skip to main content

Table 1 Patients’ Characteristics and Association with Tumor Response

From: Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience

CharacteristicsTotal (N = 118)Tumor ResponseP
value
CR/PR
(N = 15)
SD
(N = 41)
PD/NA
(N = 62)
Age, median (IQR)61.0 (14.0)61.0 (45.0)60 (15.0)61.5 (13.0).890
6574 (62.7)9 (60.0)26 (63.4)39 (62.9).972
  > 6544 (37.3)6 (40.0)15 (36.6)23 (37.1) 
Gender    .637
 Male58 (49.2)7 (46.7)18 (43.9)33 (53.2) 
 Female60 (50.8)8 (53.3)23 (56.1)29 (46.8) 
ICD-10 cancer site    .390
 C22.1 - ICCA86 (72.9)10 (66.7)33 (80.4)43 (69.4) 
 C23/C24.9 -GB/others18 (15.3)2 (13.3)4 (9.8)12 (19.4) 
 C24.0 – ECCA9 (7.6)3 (20.0)2 (4.9)4 (6.5) 
 C24.1 – Ampullary5 (4.2)02 (4.9)3 (4.7) 
Performance status    .254
 0/1102 (86.4)15 (100.0)35 (85.4)52 (83.9) 
 2/316 (13.6)06 (14.6)10 (16.1) 
NLR3.9 (3.4)3.4 (4.6)3.3 (3.1)4.4 (3.2).202
7.45100 (84.7)14 (93.3)35 (85.4)51 (82.3).559
  > 7.4518 (15.3)1 (6.7)6 (14.6)11 (17.7) 
MLR0.40 (0.32)0.26 (0.28)0.29 (0.32)0.43 (0.31).043
0.2840 (33.9)8 (53.3)19 (46.3)13 (21.0).007
  > 0.2878 (66.1)7 (46.7)22 (53.7)49 (79.0) 
PLR151.9 (121.2)173.8 (115.5)132.7 (114.4)161.7 (121.7).364
136.447 (39.8)6 (40.0)22 (53.7)19 (30.6).065
  > 136.471 (60.2)9 (60.0)19 (46.3)43 (69.4) 
Albumin (g/dL)3.8 (0.9)4.0 (1.1)3.8 (0.8)3.7 (0.8).252
3.533 (31.4)5 (33.3)8 (22.9)20 (36.4).399
  > 3.572 (68.6)10 (66.7)27 (77.1)35 (63.6) 
ALT (U/L)30.0 (34.0)30.0 (31.0)36.0 (56.0)27.0 (24.0).321
3668 (58.1)9 (60.0)21 (51.2)38 (62.3).532
  > 3649 (41.9)6 (40.0)20 (48.8)23 (37.7) 
Bilirubin (mg/dL)0.7 (0.8)0.4 (0.9)0.6 (0.9)0.7 (0.9).221
1.389 (76.1)12 (80.0)31 (75.6)46 (75.4).929
  > 1.328 (23.9)3 (20.0)10 (24.4)15 (24.6) 
ALP (U/L)159.5 (168.0)106.0 (124.5)159.0 (207.0)173.0 (147.0).108
9430 (26.8)7 (50.0)11 (29.7)12 (19.7).061
  > 9482 (73.2)7 (50.0)26 (70.3)49 (80.3) 
Creatinine (mg/dL)0.7 (0.4)0.7 (0.4)0.6 (0.3)0.7 (0.4).814
1.27115 (97.5)15 (100.0)39 (95.1)61 (98.4).470
  > 1.273 (2.5)02 (4.9)1 (1.6) 
CA19–9 (U/mL)282.4 (2808.4)221.9 (3604.4)389.9 (1952.9)260.7 (3096.2).621
3735 (29.9)5 (33.3)7 (17.1)23 (37.7).079
  > 3782 (70.1)10 (66.7)34 (82.9)38 (62.3) 
CEA (ng/mL)4.3 (15.3)4.7 (21.2)3.1 (10.3)5.6 (19.5).259
564 (54.2)8 (53.3)26 (63.4)30 (48.4).324
  > 554 (45.8)7 (46.7)15 (36.6)32 (51.6) 
Biliary drainage    .398
 None88 (74.6)9 (60.0)31 (75.7)48 (77.5) 
 Internal stenting8 (6.8)3 (20.0)3 (7.3)2 (3.2) 
 PTCD19 (16.1)3 (20.0)6 (14.6)10 (16.1) 
 Both3 (2.5)01 (2.4)2 (3.2) 
Tumor involvement
 Primary tumor    .116
  No8 (6.8)01 (2.4)7 (11.3) 
  Yes110 (93.2)15 (100.0)40 (97.6)55 (88.7) 
 Regional LAP    .585
  No42 (35.6)7 (46.7)13 (31.7)22 (35.5) 
  Yes76 (64.4)8 (53.3)28 (68.3)40 (64.5) 
 Lung    .069
  No95 (80.5)15 (100.0)34 (82.9)46 (74.2) 
  Yes23 (19.5)07 (17.1)16 (25.8) 
 Bone    .748
  No105 (89.0)14 (93.3)37 (90.2)54 (87.1) 
  Yes13 (11.0)1 (6.7)4 (9.8)8 (12.9) 
 Liver    .465
  No69 (58.5)10 (66.7)26 (63.4)33 (53.2) 
  Yes49 (41.5)5 (33.3)15 (36.6)29 (46.8) 
 Peritoneum    .436
  No96 (81.4)14 (93.3)33 (80.5)49 (79.0) 
  Yes22 (18.6)1 (6.7)8 (19.5)13 (21.0) 
 Distant LAP    .969
  No102 (86.4)13 (86.7)35 (85.4)54 (87.1) 
  Yes16 (13.6)2 (13.3)6 (14.6)8 (12.9) 
  1. Figures are numbers with percentages in parentheses, unless otherwise stated
  2. The Chi-Squared test of independence: categorical variable
  3. The Kruskal-Wallis test is a nonparametric (distribution free) test: continuous variable
  4. IQR Interquartile, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, NA Not assessed ALP Alkaline phosphatase, ALT Alanine aminotransferase, NLR Neutrophil to lymphocyte ratio, MLR Monocyte to lymphocyte ratio, PLR Platelet to lymphocyte ratio, LAP Lymphadenopathy, PTCD Percutaneous transhepatic cholangiography drainage, ICCA Intrahepatic cholangiocarcinoma, ECCA Extrahepatic cholangiocarcinoma, GB Gallbladder